查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1573007

血癌藥物市場：按藥物類型、疾病類型、治療類型、最終用戶、劑型分類 - 全球預測 2025-2030

Blood Cancer Drugs Market by Drug Type (Chemotherapy, Immunotherapy, Targeted Therapy), Disease Type (Leukemia, Lymphoma, Multiple Myeloma), Treatment Type, End-User, Drug Formulation - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年血癌藥物市場價值為427.8億美元，預計到2024年將達到459.8億美元，複合年成長率為9.90%，到2030年將達到828.7億美元。

血癌藥物的範圍集中在用於治療各種類型血癌的藥物，包括白血病、淋巴瘤和骨髓瘤。這些藥物包括化療藥物、標靶治療藥物、免疫治療藥物和幹細胞移植藥物。全球血癌盛行率不斷上升，以及提高存活率的技術創新需求推動了對這些藥物的需求。它適用於多種血癌的治療方法，有時單獨使用或與其他治療方法結合使用。最終使用領域主要包括醫院、診所和專門的癌症治療中心，它們擴大採用先進的診斷工具來客製化治療。

主要市場統計
基準年[2023] 427.8億美元
預測年份 [2024] 459.8億美元
預測年份 [2030] 828.7億美元
複合年成長率（%） 9.90%

影響市場的主要成長要素包括藥物開發的技術進步、更容易患血癌的老齡化人口的增加以及對惡性的認知和早期發現的提高。個人化醫療的興起和標靶治療的發展為透過根據患者的基因譜量身訂做治療方法來改善預後和最大限度地減少副作用提供了絕佳的機會。此外，製藥公司和研究機構之間的合作研究加速了藥物發現和商業化的進程。

相反，市場成長受到高昂的市場開拓成本、嚴格的監管要求以及限制患者依從性的現有療法的副作用的阻礙。藥品的取得和負擔能力仍然是一個問題，特別是在低收入人口眾多的地區。

最有前景的技術創新領域包括基因編輯和次世代定序技術，它們可以更精確地靶向癌細胞，並允許針對個別患者量身定做治療方法。此外，對癌症免疫療法和生物資訊學的投資增加將為研究和開發開闢途徑。市場格局是動態的，競爭環境的特徵是不斷的研發努力。因此，市場參與企業必須保持敏捷，專注於策略夥伴關係關係，並優先考慮以患者為中心的創新，以保持競爭力並推動業務成長。

市場動態：揭示快速發展的血癌藥物市場的關鍵市場洞察

供需的動態交互作用正在改變血癌藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 透過擴大醫療基礎設施和治療機會加速血癌藥物市場成長
    • 支持血癌藥物開發和可近性的政府措施和優惠政策
    • 主要企業之間的策略聯盟和夥伴關係，以加速血癌藥物開發的進展
    • 老年人口的增加和血癌易感性的增加推動了血癌藥物市場的需求
  • 市場限制因素
    • 缺乏認知和早期檢測措施影響血癌治療結果和市場成長
    • 專業治療設施和醫療保健專業人員數量有限，影響病患照護和市場潛力；
  • 市場機會
    • 血癌治療市場對個人化醫療解決方案的需求不斷成長
    • 生技藥品和標靶治療的進步推動血癌藥物的成長
    • 透過提高認知和早期診斷來提高血癌患者的治療率
  • 市場挑戰
    • 主要企業之間的激烈競爭影響血癌藥物價格和市場佔有率
    • 嚴格的監管要求和合規障礙影響血癌藥物創新

波特五力：駕馭血癌藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對血癌治療市場的影響

外部宏觀環境因素在塑造血癌治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解血癌治療藥物市場的競爭狀況

血癌治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣血癌治療市場供應商的績效評估

FPNV定位矩陣是評估血癌治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪血癌治療市場的成功之路

血癌藥物市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告提供了涵蓋關鍵重點領域的市場全面分析：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 擴大醫療基礎設施和治療的覆蓋範圍，推動血癌藥物市場的成長
      • 支持血癌藥物開發和可近性的政府措施和優惠政策
      • 主要企業之間的策略合作和夥伴關係加速了血癌藥物開發的進展
      • 老年人口的增加和血癌易感性的增加正在推動血癌治療的市場需求。
    • 抑制因素
      • 缺乏認知和早期檢測措施會影響血癌治療結果和市場成長。
      • 缺乏專門的治療設施和醫療保健專業人員會影響患者護理和市場潛力。
    • 機會
      • 血癌治療市場對個人化醫療解決方案的需求不斷成長
      • 生物製藥和標靶治療的進步推動血癌藥物的成長
      • 提高認知和早期診斷可提高血癌患者的治療率
    • 任務
      • 主要製藥公司之間的激烈競爭影響血癌藥物價格和市場佔有率
      • 嚴格的監管要求和合規障礙影響血癌藥物創新
  • 市場區隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依藥物類型分類的血癌治療市場

  • 化療
    • 烷化劑
    • 細胞週期蛋白
    • 抗代謝物
  • 免疫療法
    • CAR-T細胞療法
    • 細胞激素
    • 免疫查核點抑制劑
  • 標靶治療
    • 單株抗體
    • 蛋白酶體抑制劑
    • 蛋白酪氨酸激酶抑制劑

第7章血癌治療市場：依疾病類型

  • 白血病
    • 急性淋巴性白血病
    • 急性骨髓性白血病
    • 慢性淋巴性白血病
    • 慢性骨髓性白血病
  • 淋巴瘤
    • 何傑金氏淋巴瘤
    • 非何傑金氏淋巴瘤
  • 多發性骨髓瘤
  • 骨髓發育不良症候群

第8章依治療類型分類的血癌治療藥物市場

  • 強化治療
  • 誘導治療
  • 維持治療
  • 安寧療護

第9章血癌治療市場：依最終用戶分類

  • 門診手術中心
  • 診所
  • 居家護理
  • 醫院

第10章 藥物處方血癌治療市場

  • 肌肉注射
  • 靜脈
  • 口服
  • 皮下的

第11章北美和南美的血癌治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區血癌治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲的血癌治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-1A1A064C04E8

The Blood Cancer Drugs Market was valued at USD 42.78 billion in 2023, expected to reach USD 45.98 billion in 2024, and is projected to grow at a CAGR of 9.90%, to USD 82.87 billion by 2030.

The scope of blood cancer drugs centers on pharmaceuticals used in the treatment of different types of blood cancers, including leukemia, lymphoma, and myeloma. These drugs encompass chemotherapeutics, targeted therapies, immunotherapies, and stem cell transplantation drugs. The necessity for these drugs is driven by a growing incidence of blood cancers globally, requiring innovations to improve survival rates. Their application spans across treatment regimens for various blood cancers, sometimes used alone or in combination with other therapies. End-use scope primarily involves hospitals, clinics, and specialized cancer treatment centers, which increasingly employ advanced diagnostic tools to tailor treatments.

KEY MARKET STATISTICS
Base Year [2023] USD 42.78 billion
Estimated Year [2024] USD 45.98 billion
Forecast Year [2030] USD 82.87 billion
CAGR (%) 9.90%

Key growth factors influencing the market include technological advancements in drug development, an expanding aging population susceptible to blood cancers, and increased awareness and early detection of these malignancies. The rise of personalized medicine and the development of targeted therapies offer notable opportunities, as they tailor treatments to a patient's genetic profile, thus improving outcomes and minimizing side effects. Furthermore, collaborations between pharmaceutical companies and research institutions can accelerate drug discovery and commercialization processes.

Conversely, market growth is hindered by high costs associated with drug development, stringent regulatory requirements, and side effects of existing therapies that limit patient compliance. Accessibility and affordability, particularly in lower-income regions, remains a challenge.

The most promising areas of innovation include gene editing and next-generation sequencing technologies, which allow for more precise targeting of cancer cells and tailoring treatment to individual patients. Moreover, increased investment in cancer immunotherapy and bioinformatics presents robust avenues for research and development. The nature of the blood cancer drugs market is dynamic, with a competitive landscape characterized by continuous research and development efforts. This underscores the importance for market players to maintain agility, focus on strategic partnerships, and prioritize patient-centric innovation to remain competitive and drive business growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Blood Cancer Drugs Market

The Blood Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Expanding healthcare infrastructure and access to treatment enhancing the blood cancer drugs market growth
    • Government initiatives and favorable policies supporting the development and accessibility of blood cancer drugs
    • Strategic collaborations and partnerships among key players accelerating advancements in blood cancer drug development
    • Increasing geriatric population and their susceptibility to blood cancers driving the market demand for blood cancer therapies
  • Market Restraints
    • Lack of awareness and early detection measures affects blood cancer treatment outcomes and market growth
    • Limited availability of specialized treatment facilities and healthcare professionals impacts patient care and market potential
  • Market Opportunities
    • Increasing demand for personalized medicine solutions in the blood cancer treatment market
    • Advancements in biologics and targeted therapies driving growth in blood cancer medication
    • Growing awareness and early diagnosis leading to higher treatment rates for blood cancer patients
  • Market Challenges
    • High competition among leading pharmaceutical companies affecting blood cancer drug pricing and market share
    • Stringent regulatory requirements and compliance hurdles impacting blood cancer drug innovation

Porter's Five Forces: A Strategic Tool for Navigating the Blood Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Blood Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Blood Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Blood Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Blood Cancer Drugs Market

A detailed market share analysis in the Blood Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Blood Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Blood Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Blood Cancer Drugs Market

A strategic analysis of the Blood Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Blood Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, bluebird bio, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Company, Limited, Eisai Co., Ltd., F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., GlaxoSmithKline plc, Incyte Corporation, Johnson & Johnson, Karyopharm Therapeutics Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Seattle Genetics, Inc., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Blood Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Chemotherapy, Immunotherapy, and Targeted Therapy. The Chemotherapy is further studied across Alkylating Agents, Anthracyclines, and Antimetabolites. The Immunotherapy is further studied across CAR T-Cell Therapy, Cytokines, and Immune Checkpoint Inhibitors. The Targeted Therapy is further studied across Monoclonal Antibodies, Proteasome Inhibitors, and Tyrosine Kinase Inhibitors.
  • Based on Disease Type, market is studied across Leukemia, Lymphoma, Multiple Myeloma, and Myelodysplastic Syndrome. The Leukemia is further studied across Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Chronic Myeloid Leukemia. The Lymphoma is further studied across Hodgkin Lymphoma and Non-Hodgkin Lymphoma.
  • Based on Treatment Type, market is studied across Consolidation Therapy, Induction Therapy, Maintenance Therapy, and Palliative Therapy.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Clinics, Homecare, and Hospitals.
  • Based on Drug Formulation, market is studied across Intramuscular, Intravenous, Oral, and Subcutaneous.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Expanding healthcare infrastructure and access to treatment enhancing the blood cancer drugs market growth
      • 5.1.1.2. Government initiatives and favorable policies supporting the development and accessibility of blood cancer drugs
      • 5.1.1.3. Strategic collaborations and partnerships among key players accelerating advancements in blood cancer drug development
      • 5.1.1.4. Increasing geriatric population and their susceptibility to blood cancers driving the market demand for blood cancer therapies
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of awareness and early detection measures affects blood cancer treatment outcomes and market growth
      • 5.1.2.2. Limited availability of specialized treatment facilities and healthcare professionals impacts patient care and market potential
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing demand for personalized medicine solutions in the blood cancer treatment market
      • 5.1.3.2. Advancements in biologics and targeted therapies driving growth in blood cancer medication
      • 5.1.3.3. Growing awareness and early diagnosis leading to higher treatment rates for blood cancer patients
    • 5.1.4. Challenges
      • 5.1.4.1. High competition among leading pharmaceutical companies affecting blood cancer drug pricing and market share
      • 5.1.4.2. Stringent regulatory requirements and compliance hurdles impacting blood cancer drug innovation
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Blood Cancer Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Chemotherapy
    • 6.2.1. Alkylating Agents
    • 6.2.2. Anthracyclines
    • 6.2.3. Antimetabolites
  • 6.3. Immunotherapy
    • 6.3.1. CAR T-Cell Therapy
    • 6.3.2. Cytokines
    • 6.3.3. Immune Checkpoint Inhibitors
  • 6.4. Targeted Therapy
    • 6.4.1. Monoclonal Antibodies
    • 6.4.2. Proteasome Inhibitors
    • 6.4.3. Tyrosine Kinase Inhibitors

7. Blood Cancer Drugs Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Leukemia
    • 7.2.1. Acute Lymphocytic Leukemia
    • 7.2.2. Acute Myeloid Leukemia
    • 7.2.3. Chronic Lymphocytic Leukemia
    • 7.2.4. Chronic Myeloid Leukemia
  • 7.3. Lymphoma
    • 7.3.1. Hodgkin Lymphoma
    • 7.3.2. Non-Hodgkin Lymphoma
  • 7.4. Multiple Myeloma
  • 7.5. Myelodysplastic Syndrome

8. Blood Cancer Drugs Market, by Treatment Type

  • 8.1. Introduction
  • 8.2. Consolidation Therapy
  • 8.3. Induction Therapy
  • 8.4. Maintenance Therapy
  • 8.5. Palliative Therapy

9. Blood Cancer Drugs Market, by End-User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Clinics
  • 9.4. Homecare
  • 9.5. Hospitals

10. Blood Cancer Drugs Market, by Drug Formulation

  • 10.1. Introduction
  • 10.2. Intramuscular
  • 10.3. Intravenous
  • 10.4. Oral
  • 10.5. Subcutaneous

11. Americas Blood Cancer Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Blood Cancer Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Blood Cancer Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca PLC
  • 4. bluebird bio, Inc.
  • 5. Bristol-Myers Squibb Company
  • 6. Celgene Corporation
  • 7. Daiichi Sankyo Company, Limited
  • 8. Eisai Co., Ltd.
  • 9. F. Hoffmann-La Roche Ltd
  • 10. Gilead Sciences, Inc.
  • 11. GlaxoSmithKline plc
  • 12. Incyte Corporation
  • 13. Johnson & Johnson
  • 14. Karyopharm Therapeutics Inc.
  • 15. Merck & Co., Inc.
  • 16. Novartis International AG
  • 17. Pfizer Inc.
  • 18. Sanofi S.A.
  • 19. Seattle Genetics, Inc.
  • 20. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. BLOOD CANCER DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. BLOOD CANCER DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. BLOOD CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. BLOOD CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BLOOD CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BLOOD CANCER DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ANTHRACYCLINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MYELODYSPLASTIC SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CONSOLIDATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INDUCTION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY PALLIATIVE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 128. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 130. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 134. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 136. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 137. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 138. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 140. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 141. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 144. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 146. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 147. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 148. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 150. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 151. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 154. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 156. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 157. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 158. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 160. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 161. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 164. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 166. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 167. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 168. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 170. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 171. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 174. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 176. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 177. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 178. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 180. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 181. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 184. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 186. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 188. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 190. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 194. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 196. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 197. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 198. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 200. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 201. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 203. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 214. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 216. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 217. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 218. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 220. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 221. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 223. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 224. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 226. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 227. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 228. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 230. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 231. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 233. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 234. VIETNAM BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. VIETNAM BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 236. VIETNAM BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 237. VIETNAM BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 238. VIETNAM BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. VIETNAM BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 240. VIETNAM BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 241. VIETNAM BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. VIETNAM BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 243. VIETNAM BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 255. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 257. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 258. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 259. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 261. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 262. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 264. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 265. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 267. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 268. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 269. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 271. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 272. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 274. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 275. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 277. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 278. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 279. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 281. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 282. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 283. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 284. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 285. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 287. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 288. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 289. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 291. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 292. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 294. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 295. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 297. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 298. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 299. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 300. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 301. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 302. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 303. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 304. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 305. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 306. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 307. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 308. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 309. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 310. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 311. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 312. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 313. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 314. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 315. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 316. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 317. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 318. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 319. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 321. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 322. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 323. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 324. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 325. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 326. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 327. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 328. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 330. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 331. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 332. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 333. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 334. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 335. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 336. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 337. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 338. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 339. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 340. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 341. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 342. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 343. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 344. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 345. NORWAY BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 346. NORWAY BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 347. NORWAY BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 348. NORWAY BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 349. NORWAY BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 350. NORWAY BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 351. NORWAY BLOOD CANCER DRUGS MARKET SIZE, BY